Galena Biopharma (GALE) Receiving Somewhat Favorable Press Coverage, Analysis Shows
News coverage about Galena Biopharma (NASDAQ:GALE) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Galena Biopharma earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.8544335946173 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Immunotherapy Drugs Global Market, By Product & Data Validation, 2016 Analysis and Forecast 2022 (emailwire.com)
- Drugmaker to pay $7.5M to settle opioid kickback allegations – Dayton Daily News (daytondailynews.com)
- Galena Biopharma and BioVascular, Inc. Reaffirm GALE-401 Partnership – GlobeNewswire (press release) (globenewswire.com)
- BRIEF-Galena Biopharma and Biovascular Inc reaffirm GALE-401 partnership (reuters.com)
Several research firms recently issued reports on GALE. ValuEngine downgraded shares of Galena Biopharma from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Maxim Group reaffirmed a “hold” rating on shares of Galena Biopharma in a report on Wednesday, August 9th.
Galena Biopharma (GALE) traded up 0.917% during trading on Thursday, reaching $0.352. 131,012 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $0.41 and a 200-day moving average of $0.55. Galena Biopharma has a 12 month low of $0.16 and a 12 month high of $4.75. The stock’s market cap is $13.52 million.
Galena Biopharma (NASDAQ:GALE) last released its earnings results on Monday, August 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). During the same period in the previous year, the firm earned $0.05 earnings per share. On average, equities research analysts anticipate that Galena Biopharma will post ($0.59) earnings per share for the current fiscal year.
Galena Biopharma Company Profile
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.